AVTE 2.37 Aerovate Therapeutics, Inc.
| Range: | 1.25-32.415 | Vol Avg: | 256557 | Last Div: | 0 | Changes: | 0.05 |
| Beta: | 1.04 | Cap: | 0.07B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jun 30 2021 | Empoloyees: | 51 | ||
| CUSIP: | 008064107 | CIK: | 0001798749 | ISIN: | US0080641071 | Country: | US |
| CEO: | Mr. Timothy P. Noyes M.B.A. | Website: | https://aerovatetx.com | ||||
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow